Chronic kidney disease (CKD) is very prevalent in patients with HF, and makes the use of drugs with a favorable effect on patient prognosis more difficult, due to increased complications (hyperkalemia, impaired kidney function, hypotension). Pharmacological clinical trials in HFrEF have excluded cases with a glom...
M. A. Gámez, A. E. Fernandez, J. L. Bonilla-Palomas et al.· European Heart Journal· 0 citations
Elevated UACR independently predicts the cumulative burden of recurrent WHF in ambulatory chronic HF, with risk already detectable below the conventional 30 mg/g threshold, with risk increased continuously across the UACR spectrum with no threshold at 30 mg/g.
R. de la Espriella, Elia Martinez, Marina Reinartz et al.· Clinical Kidney Journal· 0 citations
Cardiac rehabilitation (CR) holds a Class I recommendation for heart failure (HF) patients to improve functional capacity and reduce hospitalizations. However, its implementation in real-world clinical practice remains suboptimal. This study aimed to characterize the clinical profile and comorbidities of HF patie...
A. E. Fernandez, J. L. Bonilla-Palomas, J. Muñiz et al.· European Heart Journal· 0 citations
In patients with advanced CKD, lipid control was below cardiology guideline recommendations for patients at very high cardiovascular disease risk, particularly among those without ASCVD and in women.
Ramón Garrido González, Almudena Castro, R. de la Espriella et al.· Clinical Kidney Journal· 0 citations
In this contemporary CHF population, worse kidney function identified patients with a more adverse clinical profile and poorer outcomes, although these associations were attenuated after adjustment for congestion markers and disease severity.
M. Cobo Marcos, R. de la Espriella, J. G. Ordás et al.· Revista Española de Cardiolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.